HOME >> MEDICINE >> NEWS
European commission grants "orphan" status for new acute myeloid leukaemia treatment

Wyeth-Ayerst Pharmaceuticals, the pharmaceutical division of American Home Products Corporation (NYSE:AHP),announced today that the European Commission has designated Mylotarg(gemtuzumab ozogamicin)as an "orphan medicinal product." The Commission decision follows a positive opinion adopted on 13 September 2000 by the Committee on Orphan Medicinal Products (COMP) of the European Agency for the Evaluation of Medicinal Products (EMEA).

"We anticipate that Mylotarg will become an important treatment option for European patients aged 60 and over with CD33-positive relapsed acute myeloid leukaemia (AML)," says L. Patrick Gage, Ph.D., President, Wyeth-Ayerst Research. "Its mechanism of action focuses on using antibody-antigen specificity to target delivery of potent chemotherapy to myeloid leukaemic cells. This compound represents the first product from Wyeth's promising oncology pipeline."

As a designated orphan medicinal product, Mylotarg will have access to the Commission's "centralised" procedure for assessment of the marketing authorisation application. Orphan medicinal products are intended to treat patients with rare life-threatening or very serious diseases for which no satisfactory method of treatment exists or where the product will be of significant benefit.

Orphan medicinal products do not automatically qualify for approval under "exceptional circumstances," but companies that sponsor orphan products receive incentives for bringing these products to the market and to the patient. Such incentives include the possibility of protocol assistance from the EMEA and fee reductions for all types of centralised marketing authorisation evaluation activities. If approved by the EMEA, Mylotarg would be the first product available in Europe from a new class of anticancer therapy known as "antibody-targeted chemotherapy." Mylotarg utilizes a patented linker technology with a novel potent anti-tumor antibiotic, calicheamicin.

Mylotarg is being develo
'"/>

Contact: Roseann Ward
roseann.ward@ketchumcomms.co.uk
44-0-207-465-8752
Ketchum
14-Nov-2000


Page: 1 2 3

Related medicine news :

1. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)
2. The European Society of Cardiology launches Women at Heart
3. Use of potentially inappropriate medications among elderly common in some European countries
4. European folic acid policies are not effective enough
5. New European cancer figures for 2004 major efforts needed against the big four killers
6. Third of European cancer patients use complementary and alternative therapies
7. A new service from the European Patent Office
8. European study highlights persistent 3 decade increase in childhood cancer incidence
9. European nations urged to ratify international treaty on tobacco control
10. Increased investment in radiotherapy will improve cure rates for European cancer patients
11. ESA looking for more European women to volunteer for WISE bed-rest study in Toulouse next year

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2020)... ... 2020 , ... The podiatrists and foot doctors of Advanced Foot & Ankle ... and Ann Arbor Michigan. Dr. Tomasz Biernacki states that “Podiatrists can help ... the hospital. We have been seeing patients in the hospital for the past 3 ...
(Date:5/26/2020)... ... May 26, 2020 , ... ... which certain infections can impact the brain causing post infectious encephalitis. The ... with Streptococcal Infections) and PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) could adversely attack ...
(Date:5/26/2020)... ... May 26, 2020 , ... Sex educator, activist, humanitarian, and Wicked ... Price have just received the 2020 AASECT Audio Visual Award for jessica drake's Guide ... first of its kind to feature non-actors in its demonstrations and narratives and was ...
(Date:5/21/2020)... , ... May 21, 2020 ... ... Companion to the CRC’s Guide to Coordinating Clinical Research, CenterWatch eLearning , ... research management, The CRC Trainer: An Interactive Companion to the CRC’s Guide ...
(Date:5/21/2020)... ... May 21, 2020 , ... Fujirebio Diagnostics, Inc., a ... assays, announced today that Cigna has added ROMA® (Risk of Ovarian Malignancy Algorithm) ... company dedicated to improving the health, well-being, and peace of mind of the ...
Breaking Medicine News(10 mins):
(Date:6/3/2020)... Tenn. (PRWEB) , ... June ... ... to improve patient experience throughout the care continuum, The Beryl Institute introduces ... spirit during the COVID-19 crisis and beyond. The microsite, launched in collaboration ...
(Date:6/3/2020)... ... June 03, 2020 , ... ... it has launched the cutting edge CheckIn2Work app, a first of its kind ... medical professionals. The app delivers a quick and easy self-service health attestation for ...
(Date:6/3/2020)... (PRWEB) , ... June 03, 2020 , ... ... management, Progressive Dental Marketing provides guidance at the Dental Entrepreneur Organization ... Dentistry in The NEW World: Sustaining and Thriving Going Forward.” Progressive Dental Marketing ...
Breaking Medicine Technology:
Cached News: